Mylan Q3 non-GAAP EBITDA up; merger with Upjohn approaches

• Mylan N.V. (NASDAQ:MYL) Q3 results:
• Revenues: $2,972.1M (+0.3%).
• Sales in Europe up 7%. Sales in North America down 5%.
• Net income: $185.7M (-2.2%); non-GAAP net income: $679.7M (+12.5%); EPS: $0.36 (-2.8%); non-GAAP EBITDA: $1,009.7M (+9.4%).
• Cash flow ops: $525.0M (+7.6%).
• No guidance provided.
• This is the final earnings release for Mylan. The company will merge with Pfizer's (NYSE:PFE) Upjohn unit in 10 days. The combined company will do business as Viatris.
• https://seekingalpha.com/news/3633130-mylan-q3-non-gaap-ebitda-up-9-merger-upjohn-approaches